US20210275488A1 - Novel compound isolated from cervi parvum cornu, and pharmaceutical uses thereof - Google Patents

Novel compound isolated from cervi parvum cornu, and pharmaceutical uses thereof Download PDF

Info

Publication number
US20210275488A1
US20210275488A1 US17/260,592 US201917260592A US2021275488A1 US 20210275488 A1 US20210275488 A1 US 20210275488A1 US 201917260592 A US201917260592 A US 201917260592A US 2021275488 A1 US2021275488 A1 US 2021275488A1
Authority
US
United States
Prior art keywords
glycerol
conjugated
palmitoyl
acetyl
linoleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/260,592
Other languages
English (en)
Inventor
Young Sam GOO
Ki Nam SON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FNG RESEARCH Co Ltd
Original Assignee
FNG RESEARCH Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FNG RESEARCH Co Ltd filed Critical FNG RESEARCH Co Ltd
Assigned to FNG RESEARCH CO., LTD. reassignment FNG RESEARCH CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GOO, YOUNG SAM, SON, KI NAM
Publication of US20210275488A1 publication Critical patent/US20210275488A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system

Definitions

  • the present disclosure relates to a novel compound isolated from Cervi Parvum Cornu and pharmaceutical uses thereof, and further, a chemical synthesis method of the novel compound.
  • Cervi Parvum Cornu is one obtained by cutting and drying the non-ossified horn of deer, such as Cervus nippon, Cervus elaphus , or Cervus canadensis , which belongs to the family Cervidae.
  • Cervi Parvum Cornu is traditionally widely used as a Chinese herbal medicine that represents supplements. According to the literature “Donguibogam”, it is known that Cervi Parvum Cornu has a great variety of effects, including tonic, hematic, aphrodisiac, analgesic, hematopoietic, growth promotion, heart failure treatment and function increasing effects, as well as the effects of recovering from fatigue, enhancing the vital energy of the body and enhancing the urination function of the kidneys.
  • Cervi Parvum Cornu contains various free amino acids and polysaccharides, glycosaminoglycans (GAGs), hyaluronic acid, keratin, sialic acid, cholesterol, fatty acids, phospholipids, mineral components and the like.
  • Cervi Parvum Cornu As a method of taking Cervi Parvum Cornu, a method of taking a filtrate by extracting Cervi Parvum Cornu with hot water together with various kinds of herbal medicines, or a method of taking it as a pill after crushing it with medicinal herbs and making it into a powder is mainly used, but various studies have been conducted to extract and isolate physiologically active components from Cervi Parvum Cornu using solvent extraction and fractionation methods.
  • Korean Patent Publication No. 1999-0044781 discloses that Cervi Parvum Cornu ( Cervus nippon ) is extracted with chloroform, and the chloroform extract is fractionated using silica gel column chromatography to separate five types of monoacetyldiacylglycerol compounds, among which 1-palmitoyl-2-linoleoyl-3-acetyl glycerol represented by the following Formula (PLAG, hereinafter referred to as “PLA glycerol”) has proliferation-promoting activity of hematopoietic stem cells and platelet progenitor cells. Since then, in relation to the research on the PLA glycerol, Korean Patent Publication No.
  • Patent Publication No. 2015-0021464 discloses a composition for inhibiting blood cancer or cancer metastasis
  • Korean Patent Publication No. 2015-0021465 discloses a composition for preventing or treating rheumatoid arthritis
  • Korean Patent Publication No. 2017-0005484 discloses a composition for treating leukopenia and thrombocytopenia.
  • Korean Patent Publication No. 2000-0059468 discloses that Cervi Parvum Cornu ( Cervus nippon ) is extracted with ethanol, and the ethanol extract is fractionated using silica gel column chromatography, thereby obtaining the structures of four types of new phospholipid-based compounds including a compound of the following Formula and their antifungal activity.
  • Cervi Parvum Cornu has various pharmacological activities as described above, and its ingredients are also very diverse, Therefore, there is a need for continuous research on pharmacologically active components that are not yet known.
  • One embodiment of the present disclosure provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases, which comprises as an active ingredient at least one selected from compounds represented by the following Formulas 1 to 4 by analyzing the active ingredient isolated from Cervi Parvum Cornu.
  • compositions for the prevention or treatment of leukopenia and neutropenia comprising as an active ingredient at least one selected from compounds represented by the following Formulas 1 to 4.
  • the compound represented by Formula 1 and the compound represented by Formula 2 are isomers of each other, and the compound represented by Formula 3 and the compound represented by Formula 4 are also isomers of each other.
  • the compound according to the present disclosure can be used for the prevention or treatment of inflammatory disease caused by inflammatory cytokines, for example, inflammatory diseases selected from the group consisting of atopic dermatitis, edema, dermatitis, allergy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastritis, colitis, gout, hepatic spondylitis, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, shoulder periarthritis, myositis, hepatitis, cystitis, and nephritis.
  • inflammatory diseases selected from the group consisting of atopic dermatitis, edema, dermatitis, allergy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastritis,
  • the compound according to the present disclosure can be used for the prevention or treatment of antineoplastic chemotherapy-induced neutropenia (CIN).
  • CIN antineoplastic chemotherapy-induced neutropenia
  • Yet another embodiment of the present disclosure provides a method for synthesizing 1-palmitoyl-2-conjugated linoleoyl-3-acetyl glycerol (PCA glycerol) comprising the steps of: (a) reacting palmitic acid with a compound represented by the following Formula 5 under basic conditions to synthesize 1-palmitoyl glycerol; (b) reacting the 1-palmitoyl glycerol with acetyl halide under basic conditions to synthesize 1-palmitoyl-3-acetyl glycerol; and (c) reacting the 1-palmitoyl-3-acetyl glycerol with conjugated linoleic acid under basic conditions.
  • PCA glycerol 1-palmitoyl-2-conjugated linoleoyl-3-acetyl glycerol
  • a further embodiment of the present disclosure provides a method for synthesizing 1-conjugated linoleoyl-2-palmitoyl-3-acetyl glycerol (CPA glycerol) comprising the steps of: (a) reacting conjugated linoleic acid with a compound represented by the following Formula (5) under basic conditions to synthesize 1-conjugated linoleoyl-glycerol; (b) reacting the 1-conjugated linoleoyl-glycerol with acetyl halide under basic conditions to synthesize 1-conjugated linoleoyl-3-acetyl glycerol; and (c) reacting the 1-conjugated linoleoyl-3-acetyl glycerol with palmitic acid under basic conditions.
  • CPA glycerol 1-conjugated linoleoyl-2-palmitoyl-3-acetyl
  • the conjugated linoleic acid used in the synthesis may be conjugated linoleic acid (cis-9, trans-11) or conjugated linoleic acid (trans-10, cis-12) alone or a mixture thereof.
  • the novel compounds of Examples 1 and 2 according to the present disclosure remarkably inhibited the production of representative inflammatory cytokines IL-6, IL-1 ⁇ and TNF- ⁇ and also remarkably inhibited neutropenia caused by anticancer drugs, as compared with a control group.
  • FIG. 1 a diagram showing an extraction method using three organic solvents from Cervi Parvum Cornu according to the present disclosure.
  • FIG. 2 is a diagram showing a method for fractionating extract C2 extracted from Cervi Parvum Cornu according to the present disclosure.
  • FIG. 3 is a mass spectrometry data of the fraction C2-2-E-a-Ms according to the present disclosure.
  • FIG. 4 is an LC data of the fraction C2-2-E-a-Ms according to the present disclosure.
  • FIG. 5 (A) is the UV analysis data of the fraction C2-2-E-a-Ms according to the present disclosure, (B) is the UV analysis data of PLA glycerol of Comparative Example, (C) is the UV analysis data of conjugated linoleic acid, and (D) is the UV analysis data of linoleic acid.
  • FIG. 6 is a graph showing the results of measuring cell viability by the MTT assay of the novel compounds of Examples 1 and 2 of the present disclosure.
  • FIG. 7 is a graph showing the IL-6 production-inhibiting effect of the novel compounds of Examples 1 and 2 of the present disclosure.
  • FIG. 8 is a graph showing the IL-1 ⁇ production-inhibiting effect of the novel compounds of Examples 1 and 2 of the present disclosure.
  • FIG. 9 is a graph showing the TNF- ⁇ inhibitory effect of the novel compounds of Examples 1 and 2 of the present disclosure.
  • FIG. 10 is a graph showing the NO production inhibitory effect of the novel compounds of Examples 1 and 2 of the present disclosure.
  • FIG. 11 is a graph showing the inhibitory effect of the novel compounds of Examples 1 and 2 of the present disclosure on neutropenia induced by an anticancer agent (gemcitabine).
  • FIG. 12 is a graph showing the inhibitory effect of the novel compounds of Examples 1 and 2 of the present disclosure on neutropenia induced by an anticancer agent (tamoxifen).
  • the present inventors analyzed and carried out the solvent extraction method and the fractionation method of the prior literatures from various angles in order to develop a pharmaceutical composition for the prevention or treatment of inflammatory diseases derived from Cervi Parvum Cornu, isolated a novel compound having excellent physiological activity against inflammatory diseases by the following method, confirmed that the novel compound has a significant inhibitory effect on neutropenia (CIN) induced by chemotherapy drugs, developed a novel method for synthesizing the compound, and completed the present disclosure.
  • CIN neutropenia
  • Cervi Parvum Cornu ( Cervus nippon ) was extracted sequentially using three organic solvents of hexane, chloroform, and 70% ethanol as shown in FIG. 1 , and then subjected to a silica gel column chromatography and a thin layer liquid chromatography as shown in FIG. 2 to isolate a novel compound having excellent anti-inflammatory activity.
  • each of the isolated fractions was distilled under reduced pressure and dried to obtain fractions C2-1 to C2-7.
  • the fraction C2-2 exhibited high anti-inflammatory activity effects, and the physiologically active component was fractionated again on the fraction C2-2 using silica gel column chromatography.
  • 1.8 g of the fraction C2-2 was taken. 50 ml of a mixed solution of hexane (n-Hx)/ethyl acetate (EA) (50:1) was added to 20 g of powder silica gel, swelled, and packed in the column. 1.8 g of the fraction C2-2 was dissolved in a minimum amount of n-Hx/EA (50:1, v/v) as an eluent and subjected to a silica gel column.
  • n-Hx hexane
  • EA ethyl acetate
  • 212 mg of the fraction C2-2-E was taken. 10 ml of a mixed solution of n-Hx/EA/AcOH (20:1:0.5, v/v/v) was added to 3.5 g of powder silica gel, swelled, and packed in the column. 212 mg of the fraction C2-2-E was dissolved in n-Hx/EA/AcOH (20:1:0.5, v/v/v) as an eluent and subjected to a silica gel column.
  • FIG. 3 is a mass spectrometry data of the fraction C2-2-E-a-Ms according to the present disclosure.
  • FIG. 4 is an LC data of the fraction C2-2-E-a-Ms according to the present disclosure.
  • FIG. 5 (A) is the UV analysis data of the fraction C2-2-E-a-Ms according to the present disclosure, (B) is the UV analysis data of PLA glycerol of Comparative Example, (C) is the UV analysis data of conjugated linoleic acid, and (D) is the UV analysis data of linoleic acid.
  • the mass of the active ingredient of the fraction C2-2-E-a-Ms of the present disclosure was the same as that of the known PLA glycerol isolated from Cervi Parvum Corn (Compound KJ-3 of Korean Patent Publication No. 1999-0044781).
  • the UV analysis it showed a UV analysis pattern completely different from that of PLA glycerol. Comparing the UV pattern of (C) conjugated linoleic acid and the UV pattern of (D) linoleic acid in FIG. 5 , it was confirmed that the compound of the fraction C2-2-Ea-Ms of the present disclosure has a novel structure of conjugated linoleoyl.
  • the anti-inflammatory physiologically active component according to the present disclosure are novel compounds represented by the following Formulas 1 to 4 in which acetyl, palmitoyl, and conjugated linoleoyl are bonded to a glycerol structure. This was confirmed for the first time in the present disclosure
  • the synthesis method of PCA glycerol according to the present invention includes the steps of:
  • the compound of Formula 5 is a glycerol derivative protected by a 1,3-diol compound.
  • the reaction may be carried out under basic conditions such as trimethylamine.
  • the reaction can be carried out via an anhydride reaction with the addition of pivaloyl halide.
  • 1-palmitoyl glycerol is synthesized.
  • the equivalent weight (eq.) of palmitic acid and the compound of Formula 5 is preferably 0.9:1.1 to 1.1:0.9, but is not limited thereto.
  • step (b) the equivalent weight of 1-palmitoyl glycerol and acetyl halide is preferably 1:1 to 1:1.6, but is not limited thereto.
  • step (c) in order to maximize the reaction activity of the conjugated linoleic acid, the reaction can be carried out via anhydride reaction with the addition of pivaloyl halide.
  • the equivalent weight (eq.) of 1-palmitoyl-3-acetyl glycerol and conjugated linoleic acid is preferably 0.9:1.1 to 1.1:0.9, but is not limited thereto.
  • the synthesis method of PCA glycerol according to the present invention includes the steps of:
  • step (c) reacting the 1-conjugated linoleoyl-3-acetyl glycerol with palmitic acid under basic conditions to synthesize 1-conjugated linoleoyl-2-palmitoyl-3-acetyl glycerol (CPA glycerol).
  • CPA glycerol 1-conjugated linoleoyl-2-palmitoyl-3-acetyl glycerol
  • pivaloyl halide may be added for the anhydride reaction.
  • PLA glycerol was synthesized in the same manner as in Example 1, except that linoleic acid (cis-9,cis-12) was used instead of conjugated linoleic acid (cis-9,trans-11/trans-10,cis-12).
  • HBSS was intraperitoneally injected into a mouse to extract macrophages, which was centrifuged at 3,000 rpm for 5 minutes, and then 100 units/mL of penicillin/streptomycin was added to DMEM medium with 10% fetal bovine serum (FBS), and peritoneal macrophage was isolated. It was incubated in a 37° C., 5% CO2 incubator for 24 hours, and then used in the experiment.
  • Example 1 PCA glycerol
  • Example 2 CBA glycerol
  • the medium was removed, 40 uL of MTT (5 mg/mL) reagent was dispensed and incubated for 4 hours in a CO2 incubator, the MTT reagent was removed, and 600 uL of DMSO reagent was dispensed, and then left at room temperature for 30 minutes. Then, the absorbance (OD) was measured at 540 nm with a microplate reader.
  • the cell viability was measured by the MTT assay after treatment with the compounds of Examples 1 and 2, and shown in Table 2 and the graphs of FIG. 6 below. As shown in Table 2 and FIG. 6 , it can be seen that the cell viability does not significantly differ even when treated at a maximum of 200 ⁇ g/ml. Therefore, it was confirmed that the novel compound according to the present disclosure has no cytotoxicity.
  • Example 2 ( ⁇ g/ml) group 10 100 200 10 100 200 Cell 100 ⁇ 1.2 100 ⁇ 2.1 98.3 ⁇ 1.9 98.1 ⁇ 1.2 100 ⁇ 0.9 98.3 ⁇ 1.7 98.0 ⁇ 2.8 viability (%)
  • LPS lipopolysaccharide
  • mouse peritoneal macrophages were adjusted to 3 ⁇ 10 5 cells/mL, inoculated into a 96-well plate, cultured for 24 hours, and then the compounds of Example 1 (PCA glycerol), Example 2 (CPA glycerol) and Comparative Example (PLA glycerol) were treated at different concentrations (10 ⁇ g/ml, 100 ⁇ g/ml, and 200 ⁇ g/ml, respectively), and LPS (1 ⁇ g/ml) was treated. The normal group was untreated, and the control group was treated with only LPS (1 ⁇ g/ml) on peritoneal macrophages.
  • a supernatant was obtained by centrifugation.
  • ELISA was run in microplates coated with anti-mouse IL-6, IL-1 ⁇ and TNF- ⁇ as the capture antibody. Then, the cells were washed with phosphate buffered saline (PBST) containing 0.05% Tween 20, blocked with 10% FBS, and washed with PBST. The cell culture supernatant was dispensed into the wells, and reacted at room temperature for 2 hours.
  • PBST phosphate buffered saline
  • Example 1 and Example 2 The amount of IL-6 production of the compounds of Example 1 and Example 2 were measured and shown in Table 3 and the graph of FIG. 7 below. As shown in Table 3 and FIG. 7 , it was confirmed that the compounds prepared in Examples 1 and 2 significantly reduced in the amount of IL-6 production as compared with the control group, and also exhibited significant IL-6 production inhibitory effects even in comparison with the Comparative Example.
  • Example 2 ( ⁇ g/ml) ( ⁇ g/ml) group group 10 100 200 10 100 200 10 100 200 IL-6 150 ⁇ 18 834 ⁇ 32 321 ⁇ 22 225 ⁇ 23 180 ⁇ 25 325 ⁇ 13 234 ⁇ 20 179 ⁇ 17 364 ⁇ 16 251 ⁇ 24 203 ⁇ 25 production amount (pg/ml)
  • the amount of IL-1 ⁇ production of the compounds of Examples 1 and 2 was measured, and shown in Table 4 and the graph of FIG. 8 below. As shown in Table 4 and FIG. 8 , it was confirmed that the compounds prepared in Examples 1 and 2 significantly decreased in the amount of IL-1 ⁇ production compared to the control group, and also exhibited significant inhibitory effects on IL-1 ⁇ production even in comparison with the Comparative Example.
  • the amount of TNF- ⁇ production of the compounds of Examples 1 and 2 was measured, and shown in Table 5 and the graph of FIG. 9 below. As shown in Table 5 and FIG. 9 , it was confirmed that the compounds prepared in Examples 1 and 2 significantly reduced in the amount of TNF- ⁇ production compared to the control group, and also exhibited significant inhibitory effects on TNF- ⁇ production even in comparison with the Comparative Example.
  • Example 2 ( ⁇ g/ml) ( ⁇ g/ml) group group 10 100 200 10 100 200 10 100 200 TNF- ⁇ 113 ⁇ 11 375 ⁇ 16 170 ⁇ 8 153 ⁇ 11 121 ⁇ 10 175 ⁇ 7 151 ⁇ 10 123 ⁇ 7 184 ⁇ 21 155 ⁇ 12 137 ⁇ 7 production amount (pg/ml)
  • the cultured peritoneal macrophages were suspended in DMEM containing 10% FBS, dispensed into a 96-well plate at 5 ⁇ 10 5 cells/well and incubated for 24 hours in a 37° C., 5% CO 2 incubator, and replaced with new DMEM medium. Then, the peritoneal macrophages were treated with each of the compounds of Examples 1 and 2 and Comparative Example at different concentrations (10 ⁇ g/ml, 100 ⁇ g/ml, and 200 ⁇ g/ml, respectively), and LPS (1 ⁇ g/ml) was treated. Then, the cells were incubated for 24 hours.
  • the supernatant was separated, centrifuged at 3000 rpm for 5 minutes, and the separated supernatant was dispensed onto a new microplate.
  • the normal group was untreated, and the control group was treated with only LPS (1 ⁇ g/ml) on the peritoneal macrophages.
  • FIG. 10 is a graph showing the NO production inhibitory effect of the novel compounds of Examples 1 and 2 of the present disclosure.
  • the nitrogen monoxide (NO) production rates of the compounds of Examples 1 and 2 were measured, and shown in Table 6 and the graph of FIG. 10 below. As shown in Table 6 and FIG. 10 , it was confirmed that the compounds prepared in Examples 1 and 2 significantly reduced in the NO production rate compared to the control group, and also exhibited significant inhibitory effects on the NO production even in comparison with the Comparative Example.
  • the compounds according to the present disclosure can be used for the prevention or treatment of inflammatory disease caused by inflammatory cytokines, for example, inflammatory diseases selected from the group consisting of atopic dermatitis, edema, dermatitis, allergy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastritis, colitis, gout, hepatic spondylitis, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, shoulder periarthritis, myositis, hepatitis, cystitis, and nephritis.
  • inflammatory diseases selected from the group consisting of atopic dermatitis, edema, dermatitis, allergy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastritis,
  • PLA glycerol in Comparative Example is EC-18, a candidate substance for antineoplastic chemotherapy-induced neutropenia (CIN), and is known to have recently completed Phase II clinical trials of the FDA. It has been reported to inhibit neutropenia by a mechanism of action different from that of the conventional therapeutic agent G-CSF (filgrastim) or its derivatives (pegfilgrastim).
  • mice treated with gemcitabine showed an about 45% reduction in the number of neutrophils
  • the compound of Comparative Example (PLA glycerol) showed a 14.5% reduction in the number of neutrophils
  • the compound of Example 1 (PCA glycerol) showed an about 2% reduction in the number of neutrophils
  • the compound of Example 2 (CPA glycerol) showed a 6.7% reduction in the number of neutrophils, confirming that there was a significant effect in comparison with the Comparative Example as well as the control group.
  • mice treated with tamoxifen showed an about 37% decrease in number of neutrophils
  • the compound of Comparative Example (PLA glycerol) showed a 12.9% decrease in the number of neutrophils
  • the compound of Example 1 (PCA glycerol) showed about 6.3% decrease in the number of neutrophils
  • the compound of Example 2 (CPA glycerol) showed about 8.2% decrease in the number of neutrophils, confirming that there was a significant effect in comparison with the Comparative Example as well as the control group.
  • known anticancer chemotherapy drugs can be effectively used as an inhibitory drug for neutropenia caused by Cyclophosphamide, Imatinib, Lenalidomide, Bortezomib, Pemetrexed, Methotrexate, Paclitaxel, Etoposide, Topotecan, irinotecan, Mechlorethanime, Chlorambucil, Melphalan, Carmustine (BCNU), Lomustine (CCNU), Ifosfamide, Procarbazine, dacarbazine (DTIC), Altretamine, Mesna, Cisplatin, Carboplatin, Actinomycin D, Doxorubicin, Daunorubicin, 6-Mercaptopurine, 6-Thioguanine, Idarubicin, Epirubicin, Mitoxantrone, Azathioprine, 2-Chlorodeoxyadenosine, Hydroxyurea, 5-Fluorouracil, Cytos
  • the present disclosure relates to a novel compound isolated from Cervi Parvum Cornu and pharmaceutical uses thereof, and further, a chemical synthesis method of the novel compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pediatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
US17/260,592 2018-07-16 2019-07-15 Novel compound isolated from cervi parvum cornu, and pharmaceutical uses thereof Pending US20210275488A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180082265A KR102076314B1 (ko) 2018-07-16 2018-07-16 녹용에서 분리한 신규 화합물 및 이의 약학적 용도
KR10-2018-0082265 2018-07-16
PCT/KR2019/008736 WO2020017852A1 (ko) 2018-07-16 2019-07-15 녹용에서 분리한 신규 화합물 및 이의 약학적 용도

Publications (1)

Publication Number Publication Date
US20210275488A1 true US20210275488A1 (en) 2021-09-09

Family

ID=69164568

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/260,592 Pending US20210275488A1 (en) 2018-07-16 2019-07-15 Novel compound isolated from cervi parvum cornu, and pharmaceutical uses thereof

Country Status (6)

Country Link
US (1) US20210275488A1 (ko)
EP (1) EP3824886A4 (ko)
JP (1) JP7204258B2 (ko)
KR (1) KR102076314B1 (ko)
CN (1) CN112437662B (ko)
WO (1) WO2020017852A1 (ko)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015115865A1 (ko) * 2014-02-03 2015-08-06 최원형 아르테수네이트 또는 감마리놀렌산을 포함하는 결핵의 치료 및 예방용 항결핵 조성물
US20150266803A1 (en) * 2014-03-24 2015-09-24 Enzychem Lifesciences Corporation Method for preparing monoacetyglycerols and esters thereof
US20160128966A1 (en) * 2014-05-15 2016-05-12 Enzychem Lifesciences Corporation Methods for treating leukopenia and thrombocytopenia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301629D0 (en) * 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
DE69833333T2 (de) * 1997-11-20 2006-10-19 Jhon, Gil Ja Pharmazeutische zusammensetzung enthaltend geweihextrakte von cervus nippon mit wachstumsstimulierender aktivität auf hematopoietische stammzellen und megakaryozyten
KR100283010B1 (ko) * 1997-11-20 2001-04-02 전길자 녹용 추출물을 함유하는 조혈모세포 및 혈소판 전구세포 증식촉진용 조성물
KR100519080B1 (ko) 1999-03-04 2005-10-05 전길자 녹용으로부터 추출된 항진균제
WO2005112912A1 (en) 2004-04-24 2005-12-01 Sang-Hee Kim Immunomoduating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives
KR100789323B1 (ko) * 2005-07-20 2007-12-28 주식회사 엔지켐 글리세롤 유도체의 위치 선택적 제조방법 및 그 중간체
EP3037090B1 (en) * 2013-08-19 2019-07-31 Enzychem Lifesciences Corporation Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating rheumatoid arthritis
WO2015026112A1 (ko) 2013-08-19 2015-02-26 주식회사 엔지켐생명과학 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 혈액암 또는 암전이 억제용 조성물
CN104877127B (zh) * 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
KR101817552B1 (ko) * 2016-10-13 2018-01-11 주식회사 엔지켐생명과학 모노아세틸디아실글리세롤 화합물을 함유하는 간염의 예방 또는 치료용 조성물
KR20210094996A (ko) * 2020-01-22 2021-07-30 (주) 에프엔지리서치 녹용에서 분리한 신규 화합물을 유효성분으로 하는 만성폐쇄성 폐질환의 예방 또는 치료용 약학적 조성물 또는 건강기능식품
KR20210094997A (ko) * 2020-01-22 2021-07-30 (주) 에프엔지리서치 녹용에서 분리한 신규 화합물을 유효성분으로 하는 비알코올성 지방간 질환의 예방 또는 치료용 약학적 조성물 또는 건강기능식품

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015115865A1 (ko) * 2014-02-03 2015-08-06 최원형 아르테수네이트 또는 감마리놀렌산을 포함하는 결핵의 치료 및 예방용 항결핵 조성물
US20150266803A1 (en) * 2014-03-24 2015-09-24 Enzychem Lifesciences Corporation Method for preparing monoacetyglycerols and esters thereof
US20160128966A1 (en) * 2014-05-15 2016-05-12 Enzychem Lifesciences Corporation Methods for treating leukopenia and thrombocytopenia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kenji Mori, Pheromone synthesis. Part 255: Synthesis and GC–MS analysis of pheromonal triacylglycerols of male Drosophila fruit flies, Tetrahedron, 2014, Volume 70, Issue 35, Pages 5752-5762, https://doi.org/10.1016/j.tet.2014.06.049. (Year: 2014) *

Also Published As

Publication number Publication date
JP7204258B2 (ja) 2023-01-16
EP3824886A4 (en) 2022-04-20
WO2020017852A1 (ko) 2020-01-23
CN112437662B (zh) 2024-09-06
KR20200008297A (ko) 2020-01-28
CN112437662A (zh) 2021-03-02
JP2021531275A (ja) 2021-11-18
EP3824886A1 (en) 2021-05-26
KR102076314B1 (ko) 2020-02-11

Similar Documents

Publication Publication Date Title
Tatipamula et al. Antimicrobial and anti tubercular activities of isolates and semi synthetic derivatives of lichen Ramalina leiodea (Nyl.) Nyl.
CA2398996A1 (en) Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
Grymel et al. Glycoconjugation of betulin derivatives using copper-catalyzed 1, 3-dipolar azido-alkyne cycloaddition reaction and a preliminary assay of cytotoxicity of the obtained compounds
CN101712649B (zh) 一种荷叶提取物及其单体成分和其用途
US20210275488A1 (en) Novel compound isolated from cervi parvum cornu, and pharmaceutical uses thereof
CN101332198B (zh) 6-芳基-3-取代羰基吡啶类化合物的药物用途
Dutta et al. Cordyceps militaris: A Comprehensive Study on Laboratory Cultivation and Anticancer Potential in Dalton's Ascites Lymphoma Tumor Model
KR102337717B1 (ko) 녹용에서 분리한 신규 화합물 및 이의 약학적 용도
US20070123474A1 (en) Novel loganin analogues and a process for the preparation thereof
CN103340880B (zh) 2,3-二羟基苯甲酸酯类化合物在制备治疗糖尿病的食品和药物中的应用
CN109820861A (zh) 一种具有抗肿瘤活性的吩噻嗪类衍生物的应用
CN109912653A (zh) 一种具有抗肿瘤活性的吩噻嗪类衍生物及其合成方法
KR20210094997A (ko) 녹용에서 분리한 신규 화합물을 유효성분으로 하는 비알코올성 지방간 질환의 예방 또는 치료용 약학적 조성물 또는 건강기능식품
CN102250197B (zh) 一种麦冬总甾体皂苷提取物的制备方法及应用
CN101468950B (zh) 从北青龙衣中分离的新化合物及其制备方法及应用
CN111217824B (zh) 4-o-芳氨丙基土甘草a衍生物及其制备及应用
KR101186264B1 (ko) 산자나무 추출물 또는 이로부터 분리된 화합물을 포함하는 ｉｌ-6으로 매개되는 질환 또는 라이노바이러스 감염성 질환의 예방 또는 치료용 조성물
CN114478318B (zh) 二腈异佛尔酮衍生物、其制备方法及应用
US9663551B2 (en) Solanidine-derived compounds
US20090143318A1 (en) Degranulation inhibitor
CN109762161A (zh) 水溶性异噁唑姜黄素衍生物的制备方法及其在抗肿瘤方面的应用
US8022080B2 (en) Small molecules with antiprotozoal activity
CN105732711B (zh) 2(1h)‑喹啉酮磷酸酯衍生物及其制备方法和应用
CN104557496B (zh) 单羰基类化合物、组合物及在制备药物中的应用
Turkar et al. A comprehensive review on the synthesis of mangiferin derivatives and their multiple biological activities

Legal Events

Date Code Title Description
AS Assignment

Owner name: FNG RESEARCH CO., LTD., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOO, YOUNG SAM;SON, KI NAM;REEL/FRAME:055027/0809

Effective date: 20200112

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED